UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 2019
IMMUNIC, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36201 | 56-2358443 |
(State or other jurisdiction
of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | | |
| | 1200 Avenue of the Americas, Suite 200 New York, NY 10036 USA | |
| | (Address of principal executive offices) | |
Registrant’s telephone number, including area code: 49 89 250079460
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value | IMUX | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth companyý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of theExchange Act. YesýNo¨
Item 8.01. Other Events
Effective December 4, 2019, the Board of Directors (the “Board”) of Immunic, Inc. changed the composition of its committees. The current membership of Board committees is as follows:
| · | Audit Committee: Barclay Phillips (Chair), Jan Van den Bossche and Jörg Neermann. |
| · | Compensation Committee: Tamar Howson (Chair) and Jörg Neermann. |
| · | Nominating and Governance Committee: Vincent Ossipow (Chair) and Jan Van den Bossche. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | | | | | | |
| Dated: December 6, 2019 | | | | Immunic, Inc. |
| | | | |
| | | | | By: | | /s/ Daniel Vitt |
| | | | | | | Daniel Vitt |
| | | | | | | Chief Executive Officer |
